- Home
- RVMD vs NBIX Comparison
RVMD vs NBIX Comparison
Compare RVMD & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | NBIX |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 13.9B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | RVMD | NBIX |
|---|---|---|
| Price | $95.36 | $127.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 22 |
| Target Price | $117.33 | ★ $175.27 |
| AVG Volume (30 Days) | ★ 1.6M | 858.3K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | N/A | $22.85 |
| Revenue Next Year | $454.85 | $9.99 |
| P/E Ratio | ★ N/A | $27.76 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $29.17 | $84.23 |
| 52 Week High | $124.49 | $160.18 |
Technical Indicators
Market Signals| Indicator | RVMD | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 42.17 |
| Support Level | $93.86 | $122.82 |
| Resistance Level | $107.45 | $128.99 |
| Average True Range (ATR) | 3.19 | 2.99 |
| MACD | -0.30 | 0.14 |
| Stochastic Oscillator | 8.97 | 15.83 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.